MBX Biosciences (MBX) Other Accumulated Expenses (2023 - 2026)

MBX Biosciences has reported Other Accumulated Expenses for 4 years, with the latest figure at $294000.0 in Q1 2026.

• Quarterly Other Accumulated Expenses fell 93.68% year-over-year to $294000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $294000.0 (down 93.68% YoY) and the FY2025 annual result came in at $7.4 million, up 141.72% from the prior year.
• Other Accumulated Expenses fell to $294000.0 in Q1 2026 per MBX's latest filing, from $7.4 million in the prior quarter.
• Over five years, Other Accumulated Expenses peaked at $7.4 million in Q4 2025 and troughed at $114000.0 in Q4 2023.
• A 4-year average of $2.5 million and a median of $1.8 million in 2024 frame the typical range for Other Accumulated Expenses.
• The sharpest annual moves came in 2024 and 2026: Other Accumulated Expenses soared 2586.84% in 2024, then sank 93.68% in 2026.
• Over 4 years, Other Accumulated Expenses stood at $114000.0 in 2023, then jumped by 2586.84% to $3.1 million in 2024, then surged by 141.72% to $7.4 million in 2025, then tumbled by 96.03% to $294000.0 in 2026.
• According to Business Quant data, Other Accumulated Expenses over the past three periods registered $294000.0, $7.4 million, and $572000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.